Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652527 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2SYKHTTL3MBTL1 | |
| SCHEMBL6621545 | 0.83 | HTT (0.60) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9293928 | 0.81 | LMNA (0.59) | LMNASMN1; SMN2SYKHTTHSD17B10 | |
| SCHEMBL12150014 | 0.81 | HSD17B10 (0.58) | LMNASMN1; SMN2SYKHTTL3MBTL1 | |
| SCHEMBL7378563 | 0.81 | SYK (0.57) | LMNASMN1; SMN2SYKHTTL3MBTL1 | |
| SCHEMBL5218083 | 0.81 | SYK (0.57) | LMNASMN1; SMN2SYKHTTL3MBTL1 | |
| SCHEMBL5640402 | 0.80 | LMNA (0.58) | LMNASMN1; SMN2SYKHTTL3MBTL1 | |
| SCHEMBL6216286 | 0.80 | LMNA (0.58) | LMNASMN1; SMN2SYKHTTL3MBTL1 | |
| SCHEMBL4473071 | 0.80 | LMNA (0.58) | LMNASMN1; SMN2SYKHTTL3MBTL1 | |
| SCHEMBL7285559 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2L3MBTL1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-7109200-B2 | Carbamate derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-1340753-B1 | CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20040038986-A1 | Carbamate derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1340753-A1 | CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-4447436-A | 1,2,3,4-Tetrahydroisoquinolines 6.10,7,8 dihydroxy substitute-1-methylanilino and use as smooth muscle relaxants | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-08 | — | — | US | disclosed |
| US-4367230-A | ANTIANOXIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1983-01-04 | — | — | US | disclosed |
| US-4220647-A | MUSCLE RELAXANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | LMNA 3644/4885SMN1; SMN2 1951/4885SYK 992/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | LMNA 3644/4885SMN1; SMN2 1951/4885SYK 992/4885 |
| US-20040038986-A1 | Carbamate derivatives, process for producing the same and use thereof | CFH, F11, F2 | LMNA 3173/4885SMN1; SMN2 4524/4885SYK 839/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | LMNA 3614/4885SMN1; SMN2 1986/4885SYK 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.